SCHEMBL2655475

SCHEMBL2655475

Cc1cc(SCC(C)(C)Cc2ccc(C(=O)O)s2)cc(C)c1-c1ccc(C(F)(F)F)cc1

nearest known ligand 0.39

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 19/20 0.39
PPARA Q07869 11/20 0.39
PPARG P37231 4/20 0.39
NPC1 O15118 1/20 0.35
ALDH1A1 P00352 1/20 0.35
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2656087 0.92 GRIA4 (0.39) PPARDPPARAALDH1A1
SCHEMBL2655773 0.90 PPARD (0.38) PPARDPPARAPPARG
SCHEMBL2661637 0.86 MCL1 (0.43) PPARDPPARAPPARGNPC1ALDH1A1
SCHEMBL2653312 0.83 MAPT (0.36) PPARDPPARAPPARGNPC1ALDH1A1
SCHEMBL2652568 0.83 PPARD (0.40) PPARDPPARAPPARG
SCHEMBL2655627 0.82 PPARD (0.39) PPARDPPARAPPARGALDH1A1
SCHEMBL2658618 0.82 GRIA4 (0.37) PPARDPPARAALDH1A1
SCHEMBL2655215 0.81 PPARD (0.39) PPARDPPARAPPARGALDH1A1
SCHEMBL2655360 0.81 PPARD (0.43) PPARDPPARAPPARG
SCHEMBL2656753 0.80 PPARD (0.42) PPARDPPARAPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1957484-A2 GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES Eli Lilly & Company (US) 2008-08-20 EP claimed
WO-2007120284-A2 GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2007-10-25 WO claimed
EP-1957484-A2 GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES Eli Lilly & Company (US) 2008-08-20 EP disclosed
WO-2007120284-A2 GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2007-10-25 WO disclosed